Advantages of using estimated depression-free days for evaluating treatment efficacy

Psychiatric Services

Volumn 61, Issue 2, 2010, Pages 160-163

  Vannoy, Steven D ^a   Arean, Patricia ^b   Unützer, Jürgen ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DATA ANALYSIS; DISEASE FREE INTERVAL; DYSTHYMIA; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; SYMPTOM; TREATMENT OUTCOME;

EID: 76049110993     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2010.61.2.160     Document Type: Article

References (26)

1. Mallick R, Chen J, Entsuah AR, et al: Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Journal of Clinical Psychiatry 64:321-330, 2003
2. Cohen J: A power primer. Psychological Bulletin 112:155-159, 1992
3. Riso LP, Thase ME, Howland RH, et al: A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. Journal of Affective Disorders 43:131-142, 1997
4. Lave JR, Frank RG, Schulberg HC, et al: Cost-effectiveness of treatments for major depression in primary care practice. Archives of General Psychiatry 55:645-651, 1998
5. Araya R, Flynn T, Rojas G, et al: Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. American Journal of Psychiatry 163:1379-1387, 2006
6. Ciechanowski PS, Russo JE, Katon WJ, et al: The association of patient relationship style and outcomes in collaborative care treatment for depression in patients with diabetes. Medical Care 44:283-291, 2006
7. Liu CF, Hedrick SC, Chaney EF, et al: Cost-effectiveness of collaborative care for depression in a primary care veteran population. Psychiatric Services 54:698-704, 2003
8. Montgomery SA, Andersen HF: Escitalopram versus venlafaxine XR in the treatment of depression. International Clinical Psychopharmacology 21:297-309, 2006
9. Pyne JM, Tripathi S, Williams DK, et al: Depression-free day to utility-weighted score: is it valid? Medical Care 45:357-362, 2007
10. Revicki DA, Siddique J, Frank L, et al: Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Archives of General Psychiatry 62:868-875, 2005
11. Simon GE, Barber C, Birnbaum HG, et al: Depression and work productivity: the comparative costs of treatment versus nontreatment. Journal of Occupational and Environmental Medicine 43:2-9, 2001
12. Simon RI: Suicide risk assessment: what is the standard of care? Journal of the American Academy of Psychiatry and the Law 30:340-344, 2002
13. Trivedi MH, Wan GJ, Mallick R, et al: Cost and effectiveness of venlafaxine extendedrelease and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. Journal of Clinical Psychopharmacology 24:497-506, 2004
14. Simon GE, Manning WG, Katzelnick DJ, et al: Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Archives of General Psychiatry 58:181-187, 2001
15. Katon WJ, Unützer J, Fan MY, et al: Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care 29:265-270, 2006
16. Katon W, Lin EH, Kroenke K: The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. General Hospital Psychiatry 29:147-155, 2007
17. Rost K, Pyne JM, Dickinson LM, et al: Cost-effectiveness of enhancing primary care depression management on an ongoing basis. Annals of Family Medicine 3:7-14, 2005
18. Spitzer RL, Williams JB, Kroenke K, et al: Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA 272:1749-1756, 1994
19. Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine 16:606-613, 2001
20. Derogatis LR, Lipman RS, Rickels K, et al: The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behavioral Science 19:1-15, 1974
21. Unützer J, Katon WJ, Callahan CM, et al: Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 288:2836-2845, 2002
22. Lowe B, Unützer J, Callahan et al: Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Medical Care 42:1194-1201, 2004
23. Simon GE: Evidence review: efficacy and effectiveness of antidepressant treatment in primary care. General Hospital Psychiatry 24:213-224, 2002
24. Katon WJ, Schoenbaum M, Fan MY, et al: Cost-effectiveness of improving primary care treatment of late-life depression. Archives of General Psychiatry 62:1313-1320, 2005
25. Simon GE, Katon WJ, Lin EH, et al: Costeffectiveness of systematic depression treatment among people with diabetes mellitus. Archives of General Psychiatry 64:65-72, 2007
26. Jacobson NS, Truax P: Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology 59:12-19, 1991